SEOM clinical guideline for the diagnosis and treatment of gastric cancer (GC) and gastroesophageal junction adenocarcinoma (GEJA) (2019)
Por:
Martin-Richard, M, Carmona-Bayonas, A, Custodio, AB, Gallego, J, Jimenez-Fonseca, P, Reina, JJ, Richart, P, Rivera, F, Alsina, M, Sastre, J
Publicada:
1 feb 2020
Resumen:
Gastric cancer (GC) is the fifth most common cancer worldwide with a varied geographic distribution and an aggressive behavior. In Spain, it represents the sixth cause of cancer death. In Western countries, the incidence is decreasing slightly, with an increase in gastroesophageal junction adenocarcinoma (GEJA), a different entity that we separate specifically in the guideline. Molecular biology advances have been done recently, but do not yet lead to the choice in treatment approach except in advanced disease with overexpression of HER2. Endoscopic resection in very early stage, perioperative chemotherapy in locally advanced tumors and preliminary immune therapy resulting in advanced disease are the main treatment innovations in the GC/GEJA treatment. We describe the different evidences and recommendations following the statements of the American College of Physicians.
Filiaciones:
Martin-Richard, M:
Hosp Santa Creu I Sant Pau, Med Oncol Dept, Sant Antoni Maria Claret, 167, E-08025 Barcelona, Spain
Carmona-Bayonas, A:
Hosp J M Morales Meseguer, Med Oncol Dept, Murcia, Spain
Custodio, AB:
Hosp Univ La Paz, Ctr Invest Biomed Red Canc, Med Oncol Dept, Madrid, Spain
Gallego, J:
Hosp Gen Univ Elche & Vega Baja, Med Oncol Dept, Alicante, Spain
Jimenez-Fonseca, P:
Hosp Univ Cent Asturias, Med Oncol Dept, Oviedo, Spain
Reina, JJ:
Hosp Univ Virgen Macarena, Med Oncol Dept, Seville, Spain
Richart, P:
Hosp Univ I Politecn Fe, Med Oncol Dept, Valencia, Spain
Rivera, F:
IDIVAL, Hosp Marques Valdecilla, Med Oncol Dept, Santander, Spain
Alsina, M:
Univ Autonoma Barcelona, Hosp Univ Vall Hebron, Med Oncol Dept, Barcelona, Spain
Sastre, J:
Hosp Clin Univ San Carlos, Med Oncol Dept, Madrid, Spain
Hybrid Gold
|